Stereotactic body radiotherapy (SBRT) for T2N0 (>3 cm) non-small cell lung cancer: Outcomes and failure patterns.

Purpose/objectives: Outcomes of T2N0 lung cancer patients treated with stereotactic radiotherapy are not well known.
Methods and Materials: We conducted a single institution retrospective review of patients with T2N0 NSCLC who were treated with SBRT. The local, regional, distant control rates were calculated from available clinical data. Survival outcomes were determined using the Kaplan Meier method.
Results: Fifty-six patients met our selection criteria. The two-year local control rate was 84.2%. The two and 5-year disease-free survival (DFS) and OS were 31.9% and 15.3% and 39.9% and 12.1%, respectively. Centroid BED ₁₀ > 150Gy was associated with improved DFS, (p = 0.014), and OS on univariable analysis (p=0.0132).
Conclusions: SBRT provides good local control for T2N0 NSCLC, but systemic failure remains problematic.
Competing Interests: Authors’ disclosure of potential conflicts of interest Mitchell Machtay has received grant funding from Elekta and honoraria and additional support from Elekta and Varian that is unrelated to this work. Stephen J Shamp, Saad Sheikh, Tangel Chang, Nicholas Damico, Phillip Linden, Afshin Dowlati, and Tithi Biswas declare that they have no conflict of interest
(© 2021 Old City Publishing, Inc.)